0.0321  0 (0%)		07-26 13:28
Open: 0.0321 High: 0.1053 Volume: 200		Pre. Close: Low: 0.0321 Market Cap: 1(M)

Short term
Mid term
Targets	6-month :	0.09	1-year :	0.12
Resists	First :	0.07	Second :	0.1
Pivot price	0.04
Supports	First :	0.03	Second :	0.02
MAs	MA(5) :	0.04	MA(20) :	0.04
	MA(100) :	0.05	MA(250) :	0.2
MACD	MACD :	-0.1	Signal :	0
%K %D	K(14,3) :	0	D(3) :	11.1
RSI	RSI(14): 45.1
52-week	High :	1	Low :	0.02

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ NMRD ] has closed above bottom band by 37.4%. Bollinger Bands are 214.7% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 5 days. This is a sign that the current trend might continue.

If tomorrow:	Open lower	Open higher
High:	0.11 - 0.11	0.11 - 0.11
Low:	0.03 - 0.03	0.03 - 0.03
Close:	0.03 - 0.03	0.03 - 0.03

Nemaura Medical Inc., a medical technology company, discovers, develops, and commercializes diagnostic medical devices. It provides sugarBEAT, a non-invasive continuous glucose monitoring device for use by persons with Type I and Type II diabetes, as well as screen pre-diabetic patients. The company also offers proBEAT, a wellness guidance notes, that provide prompts and educate users on factors affecting blood sugar profiles, as well as conducts diabetes prevention and reversal programs. Nemaura Medical Inc. was founded in 2009 and is based in New York, New York.

Wed, 13 Dec 2023
Nemaura Medical Inc. Receives Positive Nasdaq Listing Decision - Yahoo Finance

Mon, 04 Dec 2023
“Buzz on the Street” Show: Nemaura Medical (NASDAQ: NMRD) Update on Nasdaq Compliance Status - Financialbuzz.com

Tue, 21 Nov 2023
Nemaura Medical Inc. Secures $10 Million Non-Dilutive Credit Facility to Fuel Strategic Growth - Yahoo Finance

Tue, 12 Sep 2023
Nemaura Medical Announces Participation at HLTH 2023, Las Vegas - GlobeNewswire

Mon, 11 Sep 2023
Nemaura Medical Completes 100 Patient Study for sugarBEAT® 24-hour Wear and Reports Interim Results - GlobeNewswire

Thu, 26 Jan 2023
Nemaura Medical Receives First Purchase Order from U.S. Health Provider HealthFleet - Business Wire

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Outperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Medical - Devices
Shares Out	40 (M)
Shares Float	11 (M)
Held by Insiders	57.2 (%)
Held by Institutions	2.1 (%)
Shares Short	53 (K)
Shares Short P.Month	192 (K)

EPS	-0.39
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	-0.63
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-81.2 %
Return on Equity (ttm)	0 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	-0.28
Qtrly Earnings Growth	0 %
Operating Cash Flow	-10 (M)
Levered Free Cash Flow	-10 (M)

PE Ratio	-0.09
PEG Ratio	0
Price to Book value	-0.06
Price to Sales	0
Price to Cash Flow	-0.14

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.